Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» XMT-2056
XMT-2056
FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death
FDA Lifts Hold on Mersana’s Antibody-Drug Conjugate Following Patient Death
BioSpace
Mersana Therapeutics
XMT-2056
clinical trials
FDA
antibody drug conjugate
Flag link:
FDA pauses Mersana’s clinical trial after patient dies
FDA pauses Mersana’s clinical trial after patient dies
Endpoints
Mersana
clinical trials
FDA
patient death
cancer
XMT-2056
antibody-drug conjugate
Flag link:
GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep
GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep
Fierce Biotech
GSK
Mersana
antibody-drug conjugate
Blenrep
XMT-2056
Flag link:
